Literature DB >> 14673185

Cholecystokinin activates CCKB receptors to excite cells and depress EPSCs in the rat rostral nucleus accumbens in vitro.

Samuel B Kombian1, Kethireddy V V Ananthalakshmi, Subramanian S Parvathy, Wandikayi C Matowe.   

Abstract

The peptide cholecystokinin (CCK) is abundant in the rat nucleus accumbens (NAc). Although it is colocalized with dopamine (DA) in afferent terminals in this region, neurochemical and behavioural reports are equally divided as to whether CCK enhances or diminishes DA's actions in this nucleus. To better understand the role of this peptide in the physiology of the NAc, we examined the effects of CCK on excitatory synaptic transmission and tested whether these are dependent on DA and/or other neuromodulators. Using whole-cell recording in rat forebrain slices containing the NAc, we show that sulphated CCK octapeptide (CCK-8S), the endogenously active neuropeptide, consistently depolarized cells and depressed evoked excitatory postsynaptic currents (EPSCs) in the rostral NAc. It caused a reversible, dose-dependent decrease in evoked EPSC amplitude that was accompanied by an increase in the decay constant of the EPSC but with no apparent change in paired pulse ratio. It was mimicked by unsulphated CCK-8 (CCK-8US), a CCK(B) receptor-selective agonist, and blocked by LY225910, a CCK(B) receptor-selective antagonist. Both CCK-8S and CCK-8US induced an inward current with a reversal potential around -90 mV that was accompanied by an increase in input resistance and action potential firing. The CCK-8S-induced EPSC depression was slightly reduced in the presence of SCH23390 but not in the presence of sulpiride or 8-cyclopentyltheophylline. By contrast, it was completely blocked by CGP55845, a potent GABA(B) receptor-selective antagonist. These results indicate that CCK excites NAc cells directly while depressing evoked EPSCs indirectly, mainly through the release of GABA.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14673185      PMCID: PMC1664820          DOI: 10.1113/jphysiol.2003.056739

Source DB:  PubMed          Journal:  J Physiol        ISSN: 0022-3751            Impact factor:   5.182


  70 in total

1.  The modulation of sensorimotor gating deficits by mesolimbic cholecystokinin.

Authors:  D Feifel; N R Swerdlow
Journal:  Neurosci Lett       Date:  1997-06-20       Impact factor: 3.046

2.  Cholecystokinin (CCK) increases GABA release in the rat anterior nucleus accumbens via CCK(B) receptors located on glutamatergic interneurons.

Authors:  M Lanza; F Makovec
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2000-01       Impact factor: 3.000

3.  Quinazolinone cholecystokinin-B receptor ligands.

Authors:  M J Yu; K J Thrasher; J R McCowan; N R Mason; L G Mendelsohn
Journal:  J Med Chem       Date:  1991-04       Impact factor: 7.446

4.  Cholecystokinin receptors in mammalian brain. A comparative characterization and visualization.

Authors:  P Gaudreau; S St-Pierre; C B Pert; R Quirion
Journal:  Ann N Y Acad Sci       Date:  1985       Impact factor: 5.691

5.  Psychostimulants depress excitatory synaptic transmission in the nucleus accumbens via presynaptic D1-like dopamine receptors.

Authors:  S M Nicola; S B Kombian; R C Malenka
Journal:  J Neurosci       Date:  1996-03-01       Impact factor: 6.167

6.  Forebrain projections from cholecystokininlike-immunoreactive neurons in the rat midbrain.

Authors:  K B Seroogy; J H Fallon
Journal:  J Comp Neurol       Date:  1989-01-15       Impact factor: 3.215

7.  Differential effects of the CCKA receptor ligands PD-140,548 and A-71623 on latent inhibition in the rat.

Authors:  David J Gracey; Robert Bell; David J King
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2002-04       Impact factor: 5.067

8.  Autoradiographic Localization of Cholecystokinin A and B Receptors in Rat Brain Using [125I]d-Tyr25 (Nle28,31)-CCK 25 - 33S.

Authors:  M. Carlberg; A. L. Gundlach; L. D. Mercer; P. M. Beart
Journal:  Eur J Neurosci       Date:  1992       Impact factor: 3.386

9.  Antipsychotic potential of CCK-based treatments: an assessment using the prepulse inhibition model of psychosis.

Authors:  D Feifel; T Reza; S Robeck
Journal:  Neuropsychopharmacology       Date:  1999-02       Impact factor: 7.853

10.  Presynaptic dopamine D1 receptors attenuate excitatory and inhibitory limbic inputs to the shell region of the rat nucleus accumbens studied in vitro.

Authors:  C M Pennartz; M J Dolleman-Van der Weel; S T Kitai; F H Lopes da Silva
Journal:  J Neurophysiol       Date:  1992-05       Impact factor: 2.714

View more
  5 in total

1.  A systems genetic analysis of alcohol drinking by mice, rats and men: influence of brain GABAergic transmission.

Authors:  Laura M Saba; Beth Bennett; Paula L Hoffman; Kelsey Barcomb; Takao Ishii; Katerina Kechris; Boris Tabakoff
Journal:  Neuropharmacology       Date:  2010-12-23       Impact factor: 5.250

2.  Anticonvulsant enaminones depress excitatory synaptic transmission in the rat brain by enhancing extracellular GABA levels.

Authors:  Samuel B Kombian; Ivan O Edafiogho; Kethireddy V V Ananthalakshmi
Journal:  Br J Pharmacol       Date:  2005-08       Impact factor: 8.739

Review 3.  Satiety Associated with Calorie Restriction and Time-Restricted Feeding: Central Neuroendocrine Integration.

Authors:  Debra K M Tacad; Ashley P Tovar; Christine E Richardson; William F Horn; Nancy L Keim; Giri P Krishnan; Sridevi Krishnan
Journal:  Adv Nutr       Date:  2022-06-01       Impact factor: 11.567

4.  Delayed but not immediate effects of estrogen curtail gamma-aminobutyric acid-mediated feeding responses elicited from the nucleus accumbens shell.

Authors:  Julio C Diaz; Kate Dunaway; Elizabeth Sheil; Ken Sadeghian; Anthony Auger; Brian A Baldo
Journal:  Behav Neurosci       Date:  2022-04-07       Impact factor: 2.154

5.  An epigenomic shift in amygdala marks the transition to maternal behaviors in alloparenting virgin female mice.

Authors:  Christopher H Seward; Michael C Saul; Joseph M Troy; Payam Dibaeinia; Huimin Zhang; Saurabh Sinha; Lisa J Stubbs
Journal:  PLoS One       Date:  2022-02-22       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.